NYSE:MRK - Merck & Co. Stock Price, Price Target & More

$58.92 -0.35 (-0.59 %)

(As of 04/19/2018 05:42 AM ET)

Previous Close$59.27

Today's Range$58.59 - $59.62

52-Week Range$52.83 - $66.41

Volume11.24 million shs

Average Volume13.15 million shs

Market Capitalization$158.13 billion

P/E Ratio14.80

Dividend Yield3.24%

Beta0.78

About Merck & Co. (NYSE:MRK)

Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus treatment for dogs and cats; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with Pfizer Inc., AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., and IO Biotech. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

SymbolNYSE:MRK

CUSIP58933Y10

Webwww.merck.com

Phone908-740-4000

Debt

Debt-to-Equity Ratio0.62%

Current Ratio1.33%

Quick Ratio1.06%

Price-To-Earnings

Trailing P/E Ratio14.80

Forward P/E Ratio14.16

P/E Growth2.45

Sales & Book Value

Annual Sales$40.12 billion

Price / Sales3.96

Cash Flow$5.7427 per share

Price / Cash10.26

Book Value$12.69 per share

Price / Book4.64

Profitability

EPS (Most Recent Fiscal Year)$3.98

Net Income$2.39 billion

Net Margins6.40%

Return on Equity28.61%

Return on Assets11.85%

Miscellaneous

Employees69,000

Outstanding Shares2,696,190,000

How to Become a New Pot Stock Millionaire

Merck & Co. (NYSE:MRK) Frequently Asked Questions

What is Merck & Co.'s stock symbol?

Merck & Co. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

How often does Merck & Co. pay dividends? What is the dividend yield for Merck & Co.?

Merck & Co. announced a quarterly dividend on Tuesday, January 23rd. Stockholders of record on Thursday, March 15th will be given a dividend of $0.48 per share on Friday, April 6th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 3.26%. The ex-dividend date of this dividend is Wednesday, March 14th. View Merck & Co.'s Dividend History.

How will Merck & Co.'s stock buyback program work?

Merck & Co. announced that its Board of Directors has authorized a stock repurchase program on Saturday, December 2nd 2017, which authorizes the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to purchase shares of its stock through open market purchases. Stock buyback programs are often an indication that the company's leadership believes its stock is undervalued.

How were Merck & Co.'s earnings last quarter?

Merck & Co. (NYSE:MRK) issued its quarterly earnings data on Friday, February, 2nd. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.94 by $0.04. The company had revenue of $10.43 billion for the quarter, compared to analyst estimates of $10.48 billion. Merck & Co. had a net margin of 6.40% and a return on equity of 28.61%. The business's quarterly revenue was up 3.1% on a year-over-year basis. During the same period last year, the firm earned $0.89 earnings per share. View Merck & Co.'s Earnings History.

When is Merck & Co.'s next earnings date?

Merck & Co. is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for Merck & Co..

What guidance has Merck & Co. issued on next quarter's earnings?

Merck & Co. issued an update on its FY18 earnings guidance on Friday, February, 2nd. The company provided earnings per share guidance of $4.08-4.23 for the period, compared to the Thomson Reuters consensus estimate of $4.11. The company issued revenue guidance of $41.2-42.7 billion, compared to the consensus revenue estimate of $41.10 billion.

What price target have analysts set for MRK?

18 Wall Street analysts have issued twelve-month price targets for Merck & Co.'s stock. Their predictions range from $56.00 to $74.00. On average, they anticipate Merck & Co.'s share price to reach $66.6875 in the next year. View Analyst Ratings for Merck & Co..

Who are some of Merck & Co.'s key competitors?

Some companies that are related to Merck & Co. include Pfizer (PFE), Novartis (NVS), AbbVie (ABBV), Novo Nordisk (NVO), Abbott Laboratories (ABT), Bayer (BAYRY), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TKPYY) and Regeneron (REGN).

Who are Merck & Co.'s key executives?

Merck & Co.'s management team includes the folowing people:

Mr. Kenneth C. Frazier, Chairman, CEO & Pres (Age 63)
Mr. Robert M. Davis, CFO & Exec. VP of Global Services (Age 51)
Mr. Michael J. Holston, Exec. VP & Gen. Counsel (Age 56)
Dr. Roger M. Perlmutter, Exec. VP & Pres of Merck Research Laboratories (Age 66)
Mr. Adam H. Schechter, Exec. VP & Pres of Global Human Health (Age 53)

Has Merck & Co. been receiving favorable news coverage?

News headlines about MRK stock have been trending somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Merck & Co. earned a daily sentiment score of 0.18 on Accern's scale. They also gave media coverage about the company an impact score of 45.30 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Merck & Co.?

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merck & Co.'s stock price today?

One share of MRK stock can currently be purchased for approximately $58.92.

How big of a company is Merck & Co.?

Merck & Co. has a market capitalization of $158.13 billion and generates $40.12 billion in revenue each year. The company earns $2.39 billion in net income (profit) each year or $3.98 on an earnings per share basis. Merck & Co. employs 69,000 workers across the globe.

How can I contact Merck & Co.?

Merck & Co.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]

MarketBeat Community Rating for Merck & Co. (MRK)

Community Ranking:		2.5 out of 5 ( )
Outperform Votes:		606 (Vote Outperform)
Underperform Votes:		620 (Vote Underperform)
Total Votes:		1,226

MarketBeat's community ratings are surveys of what our community members think about Merck & Co. and other stocks. Vote "Outperform" if you believe MRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Merck & Co. (NYSE:MRK) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

18 Wall Street analysts have issued ratings and price targets for Merck & Co. in the last 12 months. Their average twelve-month price target is $66.6875, suggesting that the stock has a possible upside of 13.18%. The high price target for MRK is $74.00 and the low price target for MRK is $56.00. There are currently 5 hold ratings and 13 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.72	2.61	2.53	2.56
Ratings Breakdown:	0 Sell Rating(s) 5 Hold Rating(s) 13 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 7 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 8 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 5 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$66.6875	$66.1875	$66.8750	$70.7692
Price Target Upside:	13.18% upside	20.04% upside	7.74% upside	10.78% upside

Merck & Co. (NYSE:MRK) Consensus Price Target History

Price Target History for Merck & Co. (NYSE:MRK)

Merck & Co. (NYSE:MRK) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/17/2018	Bank of America	Boost Price Target	Buy -> Buy	$68.00 -> $70.00	Low
4/17/2018	Morgan Stanley	Upgrade	Equal Weight -> Overweight	$59.80 -> $63.00	Low
4/16/2018	BMO Capital Markets	Reiterated Rating	Buy	$65.00	High
4/13/2018	Jefferies Group	Set Price Target	Hold	$56.00	Low
4/5/2018	Barclays	Upgrade	Equal Weight -> Overweight	$62.00 -> $64.00	Low
3/12/2018	Leerink Swann	Upgrade	Market Perform -> Outperform		Low
2/14/2018	Credit Suisse Group	Lower Price Target	Outperform -> Outperform	$66.00 -> $65.00	Low
2/13/2018	DZ Bank	Upgrade	Hold -> Buy		Low
1/16/2018	SunTrust Banks	Upgrade	Hold -> Buy	$54.00 -> $72.00	High
11/24/2017	Deutsche Bank	Lower Price Target	Hold -> Hold	$62.00 -> $59.00	N/A
11/15/2017	Sanford C. Bernstein	Reiterated Rating	Buy	$64.00	N/A
11/3/2017	Cowen	Reiterated Rating	Hold	$70.00	N/A
11/1/2017	Berenberg Bank	Reiterated Rating	Hold		N/A
10/30/2017	Citigroup	Upgrade	Buy		N/A
10/30/2017	UBS	Lower Price Target	Buy	$72.00 -> $67.00	N/A
10/29/2017	JPMorgan Chase	Set Price Target	Buy	$70.00	N/A
7/29/2017	Piper Jaffray	Set Price Target	Buy	$70.00	Low
7/27/2017	Goldman Sachs	Reiterated Rating	Neutral	$70.00 -> $74.00	Medium
1/13/2017	Bryan, Garnier & Co	Initiated Coverage	Buy		N/A
1/12/2017	Guggenheim	Upgrade	Neutral -> Buy	$61.63 -> $70.00	N/A
10/27/2016	Argus	Reiterated Rating	Buy	$65.00 -> $80.00	N/A

(Data available from 4/19/2016 forward)

Merck & Co. (NYSE:MRK) Earnings History and Estimates Chart

Earnings by Quarter for Merck & Co. (NYSE:MRK)

Merck & Co. (NYSE:MRK) Earnings Estimates

2018 EPS Consensus Estimate: $4.14

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	3	$0.96	$1.01	$0.99
Q2 2018	2	$1.04	$1.11	$1.08
Q3 2018	2	$1.09	$1.13	$1.11
Q4 2018	1	$0.97	$0.97	$0.97

Merck & Co. (NYSE MRK) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/1/2018							N/A
2/2/2018	Q4 2017	$0.94	$0.98	$10.4850 billion	$10.4330 billion	View	Listen
10/27/2017	Q3 2017	$1.03	$1.11	$10.5450 billion	$10.3250 billion	View	N/A
7/28/2017	Q2 17	$0.87	$1.01	$9.7463 billion	$9.93 billion	View	N/A
5/2/2017	Q1 2017	$0.83	$0.88	$9.2539 billion	$9.4340 billion	View	Listen
2/2/2017	Q416	$0.8890	$0.89	$10.22 billion	$10.10 billion	View	Listen
10/25/2016	Q316	$0.99	$1.07	$10.17 billion	$10.50 billion	View	Listen
7/29/2016	Q216	$0.91	$0.93	$9.79 billion	$9.84 billion	View	Listen
5/5/2016	Q116	$0.85	$0.89	$9.45 billion	$9.30 billion	View	N/A
2/3/2016	Q415	$0.91	$0.93	$10.32 billion	$10.22 billion	View	Listen
10/27/2015	Q315	$0.91	$0.96	$10.11 billion	$10.10 billion	View	Listen
7/28/2015	Q215	$0.80	$0.86	$9.81 billion	$9.80 billion	View	Listen
4/28/2015	Q115	$0.75	$0.85	$9.04 billion	$9.40 billion	View	Listen
2/4/2015	Q414	$0.85	$0.87	$10.61 billion	$10.48 billion	View	Listen
10/27/2014	Q314	$0.88	$0.90	$10.66 billion	$10.56 billion	View	Listen
7/29/2014	Q214	$0.81	$0.85	$10.60 billion	$10.93 billion	View	Listen
4/29/2014	Q114	$0.79	$0.88	$10.44 billion	$10.30 billion	View	Listen
2/5/2014	Q413	$0.88	$0.88	$11.39 billion	$11.30 billion	View	Listen
10/28/2013	Q313	$0.88	$0.92	$11.19 billion	$11.03 billion	View	Listen
7/30/2013	Q2 2013	$0.82	$0.84	$11.22 billion	$11.01 billion	View	Listen
5/1/2013	Q1 2013	$0.79	$0.85	$11.09 million	$10.70 million	View	Listen
2/1/2013	Q4 2012	$0.81	$0.83	$11.46 billion	$11.70 billion	View	Listen
10/26/2012	Q312	$0.92	$0.95	$11.60 billion	$11.50 billion	View	N/A
7/27/2012		$1.02	$1.05			View	N/A
4/27/2012		$0.98	$0.99			View	N/A
2/2/2012		$0.95	$0.97			View	N/A
10/28/2011		$0.91	$0.94			View	N/A
7/29/2011		$0.94	$0.95			View	N/A
4/29/2011		$0.84	$0.92			View	N/A
2/3/2011		$0.83	$0.88			View	N/A
10/29/2010	Q3 2010	$0.83	$0.85			View	N/A
7/30/2010	Q2 2010	$0.82	$0.86			View	N/A
5/4/2010	Q1 2010	$0.75	$0.84			View	N/A
2/16/2010	Q4 2009	$0.78	$0.80			View	N/A
10/22/2009	Q3 2009	$0.82	$0.90			View	N/A
7/21/2009	Q2 2009	$0.78	$0.83			View	N/A
4/21/2009	Q1 2009	$0.77	$0.74			View	N/A
2/3/2009	Q4 2008	$0.74	$0.87			View	N/A
10/22/2008	Q3 2008	$0.79	$0.80			View	N/A
7/21/2008	Q2 2008	$0.83	$0.86			View	N/A
4/21/2008	Q1 2008	$0.85	$0.89			View	N/A
1/30/2008	Q4 2007	$0.73	$0.80			View	N/A

(Earnings results data provided by Zacks Investment Research)

Merck & Co. (NYSE:MRK) Dividend Information

Merck & Co. pays an annual dividend of $1.92 per share, with a dividend yield of 3.26%. MRK's most recent quarterly dividend payment was Friday, April 6. The company has grown its dividend for the last 6 consecutive years and is increasing its dividend by an average of 2.20% each year. Merck & Co. pays out 48.24% of its earnings out as a dividend.

Most Recent Dividend:	4/6/2018
Annual Dividend:	$1.92
Dividend Yield:	3.26%
Dividend Growth:	2.20% (3 Year Average)
Payout Ratio:	48.24% (Trailing 12 Months of Earnings) 46.15% (Based on This Year's Estimates) 44.14% (Based on Next Year's Estimates)
Track Record:	6 Years of Consecutive Dividend Growth
Frequency:	Quarterly Dividend

Dividend Payments by Quarter for Merck & Co. (NYSE:MRK)

Merck & Co. (NYSE:MRK) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
1/23/2018	quarterly	$0.48	3.52%	3/14/2018	3/15/2018	4/6/2018
11/28/2017	quarterly	$0.48		12/14/2017	12/15/2017	1/8/2018
7/25/2017	quarterly	$0.47		9/14/2017	9/15/2017	10/6/2017
5/23/2017	quarterly	$0.47	2.9%	6/13/2017	6/15/2017	7/10/2017
2/28/2017	quarterly	$0.47		3/13/2017	3/15/2017	4/7/2017
11/22/2016	quarterly	$0.47	3.05%	12/13/2016	12/15/2016	1/9/2017
7/26/2016	quarterly	$0.46	3.14%	9/13/2016	9/15/2016	10/7/2016
5/24/2016	quarterly	$0.46	3.25%	6/13/2016	6/15/2016	7/8/2016
2/23/2016	quarterly	$0.46	3.64%	3/11/2016	3/15/2016	4/7/2016
11/24/2015	quarterly	$0.46	3.43%	12/11/2015	12/15/2015	1/8/2016
7/22/2015	quarterly	$0.45	3.1%	9/11/2015	9/15/2015	10/7/2015
5/26/2015	quarterly	$0.45	3.03%	6/11/2015	6/15/2015	7/8/2015
2/24/2015	quarterly	$0.45	3.05%	3/12/2015	3/16/2015	4/8/2015
11/25/2014	quarterly	$0.45	3.01%	12/11/2014	12/15/2014	1/8/2015
7/23/2014	quarterly	$0.44	3.02%	9/11/2014	9/15/2014	10/7/2014
5/27/2014	quarterly	$0.44	3.12%	6/12/2014	6/16/2014	7/8/2014
2/25/2014	quarterly	$0.44	3.13%	3/13/2014	3/17/2014	4/7/2014
11/26/2013	quarterly	$0.44	3.53%	12/12/2013	12/16/2013	1/8/2014
7/24/2013	quarterly	$0.43	3.57%	9/12/2013	9/16/2013	10/7/2013
5/28/2013	quarterly	$0.43	3.67%	6/13/2013	6/17/2013	7/8/2013
2/26/2013	quarterly	$0.43	4%	3/13/2013	3/15/2013	4/5/2013

(Data available from 1/1/2013 forward)

Merck & Co. (NYSE MRK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.32%
Institutional Ownership Percentage: 74.60%

Insider Trading History for Merck & Co. (NYSE:MRK)

Institutional Ownership by Quarter for Merck & Co. (NYSE:MRK)

Merck & Co. (NYSE MRK) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/16/2018	Weir Mirian M. Graddick	Insider	Sell	24,000	$58.00	$1,392,000.00
2/9/2018	Wendell P Weeks	Director	Sell	5,000	$53.57	$267,850.00	5,100
1/16/2018	Michael J. Holston	EVP	Sell	12,500	$61.63	$770,375.00
1/16/2018	Weir Mirian M Graddick	Insider	Sell	60,000	$61.63	$3,697,800.00	101,484
1/12/2018	Weir Mirian M Graddick	Insider	Sell	5,000	$58.00	$290,000.00	101,484
11/8/2017	Thomas H Glocer	Director	Sell	5,000	$56.20	$281,000.00
5/12/2017	C Robert Kidder	Director	Sell	5,000	$63.54	$317,700.00	14,317
4/3/2017	Adam H Schechter	EVP	Sell	53,850	$63.48	$3,418,398.00
2/8/2017	Patricia F Russo	Director	Sell	5,000	$64.42	$322,100.00	18,148
2/6/2017	Wendell P Weeks	Director	Sell	5,000	$64.51	$322,550.00	5,100
2/3/2017	Michael J Holston	EVP	Sell	91,959	$63.96	$5,881,697.64	105,559
2/3/2017	Thomas R Cech	Director	Sell	5,000	$63.42	$317,100.00	5,100
11/10/2016	Kenneth C Frazier	Chairman	Sell	140,000	$65.03	$9,104,200.00	514,957
11/7/2016	Julie L Gerberding	EVP	Sell	85,523	$60.02	$5,133,090.46	77,762
11/2/2016	Rochelle B Lazarus	Director	Sell	20,000	$59.06	$1,181,200.00	9,594
10/3/2016	Weir Mirian M Graddick	Insider	Sell	40,800	$62.07	$2,532,456.00	128,973
9/1/2016	Adam H Schechter	EVP	Sell	39,200	$62.61	$2,454,312.00	39,200
8/10/2016	Clark Golestani	EVP	Sell	3,000	$63.03	$189,090.00
8/5/2016	Kenneth C Frazier	Chairman	Sell	392,000	$61.81	$24,229,520.00	760,877
7/5/2016	Kenneth C Frazier	CEO	Sell	60,000	$58.00	$3,480,000.00	554,856
7/5/2016	Weir Mirian M Graddick	Insider	Sell	45,000	$57.99	$2,609,550.00	123,151
7/1/2016	Adam H Schechter	EVP	Sell	50,000	$57.69	$2,884,500.00	50,000
7/1/2016	Weir Mirian M Graddick	Insider	Sell	30,000	$57.49	$1,724,700.00	162,151
5/20/2016	Clark Golestani	EVP	Sell	39,877	$54.79	$2,184,860.83	17,083
4/14/2016	Kenneth C Frazier	CEO	Sell	131,040	$56.11	$7,352,654.40	653,517
11/4/2015	Wendell P. Weeks	Director	Sell	5,000	$55.53	$277,650.00	100
10/29/2015	Adele D. Ambrose	insider	Sell	37,313	$55.08	$2,055,200.04	19,695
10/29/2015	Kenneth C. Frazier	CEO	Sell	18,666	$54.69	$1,020,843.54	438,236
10/28/2015	Peter C. Wendell	Director	Sell	5,000	$54.85	$274,250.00	1,000
5/11/2015	Adam H Schechter	EVP	Sell	10,634	$60.44	$642,718.96
5/8/2015	Julie L Gerberding	EVP	Sell	38,368	$60.99	$2,340,064.32
5/4/2015	Bruce N Kuhlik	Insider	Sell	56,064	$60.20	$3,375,052.80
4/29/2015	Bruce N Kuhlik	Insider	Sell	156,902	$59.82	$9,385,877.64
4/29/2015	Michael J Holston	EVP	Sell	95,624	$59.84	$5,722,140.16
2/18/2015	Kenneth C Frazier	CEO	Sell	5,164	$58.67	$302,971.88
2/11/2015	Willie A Deese	Insider	Sell	135,864	$58.56	$7,956,195.84
2/9/2015	Peter C Wendell	Director	Sell	5,000	$58.76	$293,800.00
1/15/2015	Adam H Schechter	EVP	Sell	74,200	$62.48	$4,636,016.00
1/9/2015	Kenneth C Frazier	CEO	Sell	8,840	$62.47	$552,234.80
12/10/2014	Kenneth C Frazier	CEO	Sell	9,846	$60.00	$590,760.00
12/8/2014	Bruce N Kuhlik	Insider	Sell	50,000	$62.00	$3,100,000.00
11/26/2014	Rochelle B Lazarus	Director	Sell	10,000	$59.63	$596,300.00
11/24/2014	Wendell P Weeks	Director	Sell	5,000	$59.13	$295,650.00
11/10/2014	Kenneth C Frazier	CEO	Sell	10,000	$57.98	$579,800.00
10/10/2014	Kenneth C Frazier	CEO	Sell	9,895	$59.73	$591,028.35
9/10/2014	Kenneth C Frazier	CEO	Sell	9,814	$60.48	$593,550.72
8/25/2014	Adam H Schechter	EVP	Sell	22,000	$59.70	$1,313,400.00
8/11/2014	Kenneth C Frazier	CEO	Sell	10,058	$57.00	$573,306.00
8/4/2014	Adele D Ambrose	Insider	Sell	28,669	$56.64	$1,623,812.16
7/10/2014	Kenneth C Frazier	CEO	Sell	9,987	$58.03	$579,545.61
7/7/2014	Weir Mirian M Graddick	Insider	Sell	180,047	$59.16	$10,651,580.52
6/27/2014	Willie A Deese	Insider	Sell	72,290	$58.26	$4,211,615.40
6/10/2014	Kenneth C Frazier	CEO	Sell	9,985	$58.06	$579,729.10
5/14/2014	Adam Schechter	EVP	Sell	10,527	$55.91	$588,564.57
4/10/2014	Kenneth Frazier	CEO	Sell	10,047	$57.24	$575,090.28	310,494
4/4/2014	Bruce Kuhlik	Insider	Sell	145,225	$56.43	$8,195,046.75	121,845
2/14/2014	Clark Golestani	EVP	Sell	5,990	$55.47	$332,265.30	6,046
2/13/2014	Bridgette Heller	VP	Sell	43,870	$55.04	$2,414,604.80	27,587
2/11/2014	Adam Schechter	EVP	Sell	18,000	$55.61	$1,000,980.00
2/11/2014	John Canan	Insider	Sell	10,000	$55.70	$557,000.00	10,697
2/11/2014	Kenneth Frazier	CEO	Sell	41,520	$54.52	$2,263,670.40	262,829
2/10/2014	Peter Wendell	Director	Sell	5,000	$54.44	$272,200.00	1,000
2/10/2014	Willie Deese	Insider	Sell	50,000	$54.68	$2,734,000.00	106,049
8/7/2013	Willie Deese	Insider	Sell	50,638	$48.55	$2,458,474.90	106,040
5/15/2013	Adele D Ambrose	Insider	Sell	34,208	$46.66	$1,596,145.28
5/13/2013	Bridgette P Heller	VP	Sell	5,404	$46.15	$249,394.60
8/9/2012	Willie A Deese	Insider	Sell	62,324	$44.26	$2,758,460.24

(Data available from 1/1/2013 forward)

Merck & Co. (NYSE MRK) News Headlines

Source:

Date	Headline
	Benzinga's Top Analyst Calls From April 18, 2018 finance.yahoo.com - April 18 at 4:24 PM
	Merck Posts Another Advance In The Lucrative Lung Cancer Market seekingalpha.com - April 18 at 9:56 AM
	Merck & Co. Expected to Post Q1 2018 Earnings of $1.01 Per Share (MRK) www.americanbankingnews.com - April 18 at 7:52 AM
	Weir Mirian M. Graddick Sells 24,000 Shares of Merck & Co. (MRK) Stock www.americanbankingnews.com - April 17 at 7:11 PM
	One Up, One Down: Morgan Stanley Flips Merck, Bristol-Myers Ratings www.msn.com - April 17 at 4:28 PM
	Merck (MRK) Shares Cross Above 200 DMA www.nasdaq.com - April 17 at 4:28 PM
	Why Merck Is Betting Big on One Cancer Drug www.wsj.com - April 17 at 4:28 PM
	Merck & Co. (MRK) Lifted to "Buy" at Zacks Investment Research www.americanbankingnews.com - April 17 at 12:47 PM
	Merck & Co. (MRK) Given New $70.00 Price Target at Bank of America www.americanbankingnews.com - April 17 at 11:01 AM
	Merck Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease Vaccine finance.yahoo.com - April 17 at 9:45 AM
	Merck Begins Two Phase 3 Studies Of Pneumococcal Disease Vaccine PCV-15 (V114) www.nasdaq.com - April 17 at 9:45 AM
	Merck Wins Big Against Rivals in Lung Cancer Study Survival Rates www.msn.com - April 17 at 9:45 AM
	Expectations from Novartis’s 1Q18 Earnings finance.yahoo.com - April 17 at 9:45 AM
	Merck & Co. (MRK) Raised to "Buy" at Morgan Stanley www.americanbankingnews.com - April 17 at 8:10 AM
	Dow Movers: DIS, MRK - Presented by: The Aol. On Network www.nasdaq.com - April 16 at 4:28 PM
	Merck & Co Inc. (MRK) Is Climbing On Study Results www.nasdaq.com - April 16 at 4:28 PM
	UnitedHealth, Merck Lift the Dow Monday 247wallst.com - April 16 at 4:28 PM
	Was Merck & Co Inc.’s (NYSE:MRK) Earnings Decline Part Of A Broader Industry Downturn? finance.yahoo.com - April 16 at 4:28 PM
	Merck Notches Key Win Over Bristol-Myers on Lung Cancer Study Data www.thestreet.com - April 16 at 4:28 PM
	Merck's Keytruda Reduces Death Risk in Melanoma Patients www.zacks.com - April 16 at 9:46 AM
	Today’s Research Reports on Trending Tickers: Aphria and Merck & Company finance.yahoo.com - April 16 at 9:46 AM
	Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed (ALIMTA®) and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as First-Line Treatment for Advanced Nonsquamous NSCLC in Phase 3 KEYNOTE-189 Study finance.yahoo.com - April 16 at 9:46 AM
	Bristol-Myers says cancer drug combo reduces death risk finance.yahoo.com - April 16 at 9:46 AM
	Bristol-Myers Says Lung Cancer Drug Combination Met Trial Goal finance.yahoo.com - April 16 at 9:46 AM
	[$$] New Drug Combinations Improve Survival in Lung Cancer finance.yahoo.com - April 16 at 9:46 AM
	Merck & Co. (MRK) Rating Reiterated by BMO Capital Markets www.americanbankingnews.com - April 16 at 7:01 AM
	Merck & Co. (MRK) Expected to Post Q1 2018 Earnings of $0.99 Per Share www.americanbankingnews.com - April 16 at 1:19 AM
	Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Disease Recurrence or Death by More than 40 Percent Compared to Placebo as Adjuvant Therapy in Resected, High-Risk Stage III Melanoma finance.yahoo.com - April 15 at 4:30 PM
	Merck & Co. (MRK) Price Target Raised to $72.00 www.americanbankingnews.com - April 15 at 8:37 AM
	[$$] Why Merck Is Betting Big on One Cancer Drug finance.yahoo.com - April 15 at 8:25 AM
	Merck & Co. (MRK) Raised to Hold at BidaskClub www.americanbankingnews.com - April 14 at 5:18 PM
	Zacks Investment Research Lowers Merck & Co. (MRK) to Hold www.americanbankingnews.com - April 14 at 10:05 AM
	Incyte's Failure With Merck's Keytruda Has No Implications For OncoSec seekingalpha.com - April 13 at 4:25 PM
	Lung cancer battle brews finance.yahoo.com - April 13 at 4:25 PM
	Merck & Co. (MRK) Given a $56.00 Price Target by Jefferies Group Analysts www.americanbankingnews.com - April 13 at 10:37 AM
	Your post-surgery pain is this San Francisco drugmaker's gain and opioid users may benefit, too finance.yahoo.com - April 12 at 4:25 PM
	Merck & Co., Inc. (MRK) Lowered to Sell at BidaskClub www.americanbankingnews.com - April 11 at 8:59 PM
	Merck & Co., Inc. (MRK) Lifted to Hold at www.americanbankingnews.com - April 11 at 8:26 PM
	Merck & Co., Inc. (MRK) Receives Consensus Recommendation of "Buy" from Analysts www.americanbankingnews.com - April 11 at 7:35 PM
	Novartis’s Valuation and Analysts’ Recommendations on April 11 finance.yahoo.com - April 11 at 4:24 PM
	A shingles vaccine can improve your health — especially if you’re over 50 finance.yahoo.com - April 11 at 4:24 PM
	Why Barclays Upgraded Merck to ‘Overweight’ on April 5 finance.yahoo.com - April 11 at 10:17 AM
	3 Reasons to Be Bullish on Merck & Co., Inc. Stock investorplace.com - April 10 at 4:22 PM
	This one thing can improve your health — especially if you’re over 50 finance.yahoo.com - April 10 at 4:22 PM
	3 Reasons to Be Bullish on Merck & Co., Inc. Stock investorplace.com - April 10 at 12:10 PM
	Merck's Keytruda Offers Survival Benefit in Lung Cancer Study finance.yahoo.com - April 10 at 9:55 AM
	A Closer Look at Pfizer Stock in 1Q18 finance.yahoo.com - April 10 at 9:55 AM
	Stocks Pare Gains As Apple Tests Support Again; Bitcoin Drops finance.yahoo.com - April 9 at 4:24 PM
	US STOCKS-Wall St indexes rise over 1 pct as trade worries ease finance.yahoo.com - April 9 at 4:24 PM
	Merck's Keytruda meets main goal in pivotal lung cancer trial finance.yahoo.com - April 9 at 10:03 AM

Merck & Co. (NYSE:MRK) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Merck & Co. (NYSE:MRK) Income Statement, Balance Sheet and Cash Flow Statement

Merck & Co. (NYSE MRK) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff